AbbVie IncNYSE:ABBV
- LAST PRICE167.1750
- TODAY'S CHANGE (%)1.7350 (1.0487%)
- Bid / Lots167.1600/ 1
- Ask / Lots167.1900/ 3
- Open / Previous Close165.4900 / 165.4400
- Day Range
- 52 Week Range
- Volume1,918,951
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ABBV |
|---|---|---|
| 09:32 ET | 2049 | 165.42 |
| 09:34 ET | 68598 | 165.1218 |
| 09:36 ET | 15711 | 165.42 |
| 09:38 ET | 9847 | 165.515 |
| 09:39 ET | 7386 | 165.635 |
| 09:41 ET | 10604 | 165.795 |
| 09:43 ET | 11199 | 165.97 |
| 09:45 ET | 23602 | 166.52 |
| 09:48 ET | 39306 | 166.97 |
| 09:50 ET | 77726 | 167.23 |
| 09:52 ET | 17697 | 167.3 |
| 09:54 ET | 8308 | 167.28 |
| 09:56 ET | 9380 | 167.53 |
| 09:57 ET | 14055 | 167.52 |
| 09:59 ET | 17174 | 167.75 |
| 10:01 ET | 42786 | 167.56 |
| 10:03 ET | 21275 | 167.41 |
| 10:06 ET | 12343 | 167.34 |
| 10:08 ET | 7240 | 167.5 |
| 10:10 ET | 10914 | 167.345 |
| 10:12 ET | 31699 | 167.125 |
| 10:14 ET | 15260 | 166.96 |
| 10:15 ET | 11213 | 167.09 |
| 10:17 ET | 17210 | 167.32 |
| 10:19 ET | 20736 | 167.31 |
| 10:21 ET | 21731 | 167.345 |
| 10:24 ET | 5337 | 167.34 |
| 10:26 ET | 10428 | 167.385 |
| 10:28 ET | 34830 | 167.495 |
| 10:30 ET | 11815 | 167.69 |
| 10:32 ET | 15413 | 167.55 |
| 10:33 ET | 10385 | 167.34 |
| 10:35 ET | 6815 | 167.29 |
| 10:37 ET | 8987 | 167.38 |
| 10:39 ET | 8615 | 167.24 |
| 10:42 ET | 15463 | 167.51 |
| 10:44 ET | 15492 | 167.72 |
| 10:46 ET | 32587 | 167.44 |
| 10:48 ET | 10789 | 167.42 |
| 10:50 ET | 7392 | 167.24 |
| 10:51 ET | 6618 | 167.245 |
| 10:53 ET | 6200 | 167.2911 |
| 10:55 ET | 22925 | 167.5166 |
| 10:57 ET | 13101 | 167.4 |
| 11:00 ET | 15836 | 167.22 |
| 11:02 ET | 9206 | 167.34 |
| 11:04 ET | 6142 | 167.18 |
| 11:06 ET | 6727 | 167.35 |
| 11:08 ET | 19791 | 167.66 |
| 11:09 ET | 10617 | 167.71 |
| 11:11 ET | 9130 | 167.67 |
| 11:13 ET | 7770 | 167.555 |
| 11:15 ET | 9639 | 167.5125 |
| 11:18 ET | 4995 | 167.43 |
| 11:20 ET | 19190 | 167.62 |
| 11:22 ET | 11068 | 167.63 |
| 11:24 ET | 5023 | 167.33 |
| 11:26 ET | 9877 | 167.401 |
| 11:27 ET | 6156 | 167.49 |
| 11:29 ET | 5584 | 167.33 |
| 11:31 ET | 10353 | 167.42 |
| 11:33 ET | 12949 | 167.54 |
| 11:36 ET | 10070 | 167.48 |
| 11:38 ET | 43867 | 167.35 |
| 11:40 ET | 25470 | 167.525 |
| 11:42 ET | 7959 | 167.6 |
| 11:44 ET | 16770 | 167.58 |
| 11:45 ET | 17735 | 167.8125 |
| 11:47 ET | 18922 | 167.65 |
| 11:49 ET | 21053 | 167.55 |
| 11:51 ET | 12472 | 167.47 |
| 11:54 ET | 7860 | 167.56 |
| 11:56 ET | 7423 | 167.59 |
| 11:58 ET | 11865 | 167.6 |
| 12:00 ET | 3304 | 167.665 |
| 12:02 ET | 5699 | 167.5977 |
| 12:03 ET | 2933 | 167.535 |
| 12:05 ET | 1184 | 167.505 |
| 12:07 ET | 17655 | 167.42 |
| 12:09 ET | 12737 | 167.475 |
| 12:12 ET | 13782 | 167.5634 |
| 12:14 ET | 10304 | 167.45 |
| 12:16 ET | 16357 | 167.35 |
| 12:18 ET | 12846 | 167.445 |
| 12:20 ET | 4463 | 167.37 |
| 12:21 ET | 3960 | 167.35 |
| 12:23 ET | 6489 | 167.3213 |
| 12:25 ET | 12229 | 167.365 |
| 12:27 ET | 2839 | 167.28 |
| 12:30 ET | 26085 | 167.325 |
| 12:32 ET | 5832 | 167.42 |
| 12:34 ET | 8884 | 167.55 |
| 12:36 ET | 15270 | 167.57 |
| 12:38 ET | 7061 | 167.615 |
| 12:39 ET | 5710 | 167.68 |
| 12:41 ET | 5251 | 167.72 |
| 12:43 ET | 4539 | 167.58 |
| 12:45 ET | 8724 | 167.495 |
| 12:48 ET | 13538 | 167.4 |
| 12:50 ET | 11420 | 167.2825 |
| 12:52 ET | 15136 | 167.3177 |
| 12:54 ET | 8736 | 167.245 |
| 12:56 ET | 2791 | 167.14 |
| 12:57 ET | 5342 | 167.175 |
Today
Calling All Cerevel Therapeutics Holdings, Inc. (CERE) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your Losses, from 2 hours ago by Dow Jones
2 hours ago by Dow JonesAbbVie Announces Positive Topline Results from Phase 2 PICCOLO Trial Evaluating Mirvetuximab Soravtansine (ELAHERE(R)) for High Folate Receptor-Alpha (FR
) Expressing Platinum-Sensitive Ovarian Cancer, from 4 hours ago by Dow Jones 4 hours ago by Dow JonesSkinMedica(R) Celebrates 25 Years of Empowering Radiant Skin, from 4 hours ago by Dow Jones
4 hours ago by Dow JonesAbbVie Launches First-of-its-Kind Contest to Empower People Living with Migraine in their Careers, from 5 hours ago by Dow Jones
5 hours ago by Dow Jones
Yesterday
Calling All Cerevel Therapeutics Holdings, Inc. (CERE) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your Losses, from 11:02AM ET on Wednesday Jun 05, 2024 by Dow Jones
11:02AM ET on Wednesday Jun 05, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
AbbVie Inc | 284.7B | 49.8x | -6.05% |
Merck & Co Inc | 318.0B | 145.2x | -43.23% |
AstraZeneca PLC | 240.7B | 39.7x | +17.52% |
Novartis AG | 226.2B | 24.0x | -5.59% |
Pfizer Inc | 162.4B | -476.1x | -7.10% |
Roche Holding AG | 209.5B | 16.8x | +3.28% |
Company Information
AbbVie Inc. is a diversified research-based biopharmaceutical company. The Company is engaged in the research and development, manufacturing, commercialization and sale of medicines and therapies. It offers products in therapeutic categories, including immunology, which include Humira, Skyrizi and Rinvoq; oncology, which include Imbruvica, Venclexta/Venclyxto, Epkinly and Elahere; aesthetics products, which include Botox Cosmetic, The Juvederm Collection of Fillers and others; neuroscience, which include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy and Qulipta; eye care, which consists of Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis and Other eye care, and other key products, which include Mavyret/Maviret, Creon, Lupron, Linzess/Constella and Synthroid. It also offers investigational asset named NX-13, oral NLRX1 agonist (a member of the NOD-like receptor family), which is in Phase II for the treatment of ulcerative colitis (UC) and Crohn's disease (CD).
Contact Information
- Headquarters
- 1 N Waukegan RdNORTH CHICAGO, IL, United States 60064
- Phone
- 847-932-7900
- Fax
- 302-655-5049
Executives
- Executive Chairman of the Board
- Richard Gonzalez
- Chief Executive Officer, Director
- Robert Michael
- Chief Financial Officer, Executive Vice President
- Scott Reents
- Chief Human Resource Officer, Executive Vice President
- Timothy Richmond
- Executive Vice President, General Counsel, Company Secretary
- Perry Siatis
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $284.7B |
|---|---|
Revenue (TTM) | $54.4B |
Shares Outstanding | 1.8B |
Dividend Yield | 3.71% |
Annual Dividend Rate | 6.2000 USD |
Ex-Dividend Date | 04-12-24 |
Pay Date | 05-15-24 |
Beta | 0.58 |
EPS | $3.36 |
Book Value | $5.87 |
P/E Ratio | 49.8x |
Price/Sales (TTM) | 5.2 |
Price/Cash Flow (TTM) | 19.4x |
Operating Margin | 23.50% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
